Background:Chronic respiratory diseases rate has been increasing alarmingly, causing huge burden on the mortality and morbidity. Environmental pollution and occupational exposure, the major identified risk factors and endless adverse effects of conventional medicine put forward the need for better alternative options. Electuaries are the pharmaceutical formulation of poly herbal drugs that are employed as effective remedy for respiratory disorders in Unani system of medicine.Objective:The aim is to assess the effectiveness of Unani pharmaco-therapeutics in the management of various respiratory diseases and the computation of drug/water and drug/sugar ratio for the elaborated electuaries.Methods:A web-based review on certain selected Unani drugs and its molecular mechanism was carried out using the data bases such as Pub Med, Google Scholar, Science Direct and Scopus published until the end of June 2022.Results:It was observed that several single drugs such as Khayarshambar (Cassia fistula L.), Sapistan (Cordia dichotama Forst), Asl-us- Soos (Glycyrrhiza glabra L.), Khatmi (Althea officianialis L.), Za’fran (Crocus sativus L.), Behīdāna (Cydonia oblonga Mill.) etc. used in Unani formulations claimed to be effective in management of respiratory diseases like COVID 19. The herbs and its chemical constituents showed the preventive effect on respiratory diseases with inflammatory cell mediators, lung pathologies, airway response and immunomodulatory effects. The results of research studies (preclinical, clinical or in silico) and their molecular mechanisms on Electuaries have proved to be optimal for the respiratory system.Conclusion:Unani poly-pharmaceutics showed anti-inflammatory, anti-viral, anti-bacterial, anti-allergic, anti- tussive, mucolytic actions arresting respiratory diseases.

2024-12-01·Current Traditional Medicine

The Sequelae of Sleeping Issues and their Management in Post COVID- 19: A Unani and Contemporary Narrative Review

作者: Ara, Shabnam Anjum ; Akhlaq, Shaheen ; Siddiqui, Aisha ; Itrat, Malik ; Jamal, Anwar

Background:The Coronavirus disease (COVID-19) impacted not only physical health but also psychological health, including anxiety, depressive symptoms, and sleep issues. Disrupted sleep has now become a global concern and burden in the post-COVID period of recovery. The Unani system of medicine elaborated on sleeping issues and their management during the pandemic. However, the claims of the Unani system and its medications in improving the various domains of sleep quality during the revival period have not been investigated.Materials and Methods:A search of electronic databases on Pub Med, Scopus, Web of Science, and CINAHL, on sleep disorders, post-COVID-19 and a manual search of Unani classical text related to sleep quality improvement methods was conducted.Results:Recent scientific evidence has found a positive association between COVID-19 and sleep disorders. Unani medicine suggests improvement of sleep issues by maintaining six essential factors, dieto-therapy, pharmacotherapy, and regimens (like Nutool (irrigation), Hamam (Turkish bath), and Dalk (massage). Several pre-clinical and clinical trials done on Unani herbs (single and poly-herbal preparations) have elucidated the scientific rationale for improving sleep quality.Conclusion:Unani therapy has sufficient potential for improving sleep outcomes for COVID-19 patients as they are efficacious, safe and affordable therapeutic options. Additionally, there is still a need for evidence to support the validity of Unani psychotherapy as a multifaceted and holistic approach.

2024-10-15·Drug Metabolism and Personalized Therapy

Effect of a polyherbal Unani formulation on left ventricular diastolic dysfunction in hypertensive patients – a randomized single blind placebo controlled clinical trial

Article

作者: Riyazuddin, Mohd ; Siddiqui, Mansoor Ahmad ; Khanum, Asia ; Shahid, Arisha ; Khan, Javed Ali

AbstractObjectivesDiastolic dysfunction represents an important pathophysiological intermediate between hypertension and heart failure. In the last two decades, the prevalence of heart failure patients having normal or near normal ejection fraction (EF) has increased to around 60 %. It thus poses a great morbidity and mortality risk to the population. In view of present scenario of high prevalence, lack of evidence-based therapy, and limited clinical trials, this study aimed to evaluate how a Unani formulation affects the improvement of the left ventricular diastolic function.MethodsThis clinical trial was set up as a randomized, placebo-controlled study involving 35 participants, with 18 individuals in the test group and 17 in the control group. Test group received 3.5 g of a polyherbal Unani formulation in capsule form along with 35 mL of an extract of Borago officinalis L. (Arq-e-Gaozaban), divided into two doses after meals. Meanwhile, the control group received a placebo in the same manner over an eight-week period. Follow-ups were conducted every 15 days to assess both subjective and objective parameters in all participants.ResultsThe test formulation shows significant improvement in dyspnea and diastolic function from baseline to the end of trial (p<0.05), slight improvement in palpitations (p>0.05) and highly significant improvement in easy fatigability (p=0.001) as compared to the control.ConclusionsThe present study shows the effectiveness of the test drug in enhancing the diastolic function of left ventricle and alleviating other symptoms associated with ventricular diastolic dysfunction. Nevertheless, additional research with longer follow-up durations is necessary to clarify its efficacy and establish optimal treatment approaches for ventricular diastolic dysfunction in Unani medicine.

100 项与 National Institute of Unani Medicine 相关的药物交易

登录后查看更多信息

100 项与 National Institute of Unani Medicine 相关的转化医学

登录后查看更多信息